NEW YORK (GenomeWeb) – Kailos Genetics has signed an agreement to allow Illumina to market its TargetRich research solutions for pharmacogenetic target enrichment.

The products included in the marketing and promotions arrangement are TargetRich PGxComplete and Kailos Blue. According to Kailos, PGxComplete is a research use only reagent for targeting genes that are associated with response to more than 100 medications. Kailos Blue is the company's automated data analysis solution and reporting software used with TargetRich reagents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.